Renee Brissette

Title: Innovations of Inventor Renee Brissette

Introduction

Renee Brissette is an accomplished inventor based in Clarksburg, NJ (US). She holds a total of five patents, showcasing her significant contributions to the field of biotechnology. Her work primarily focuses on peptide sequences that interact with insulin and growth hormone receptors, which have potential therapeutic applications.

Latest Patents

One of her latest patents involves insulin and IGF-1 receptor agonists and antagonists. This invention discloses peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors, exhibiting either agonist or antagonist activity. The invention identifies at least two different binding sites present on these receptors, selectively binding the peptides. As agonists, these peptides may be developed as therapeutics to supplement or replace endogenous peptide hormones. Additionally, the antagonist peptides may also be developed for therapeutic use. Another significant patent provides peptides that bind to the active site of the growth hormone receptor. This invention includes methods for using these peptides to identify small organic molecules that act as novel agonists or antagonists of the growth hormone receptor. Furthermore, it provides kits and therapeutic compositions comprising these peptides.

Career Highlights

Renee Brissette has made notable strides in her career, particularly through her work at Antyra Inc. Her innovative research has led to advancements in understanding peptide interactions with critical hormone receptors, paving the way for new therapeutic options.

Collaborations

Throughout her career, Renee has collaborated with esteemed colleagues, including Arthur J Blume and Renuka Pillutla. These collaborations have contributed to her success and the development of her patented inventions.

Conclusion

Renee Brissette's contributions to biotechnology through her innovative patents highlight her role as a leading inventor in the field. Her work on peptide sequences for insulin and growth hormone receptors has the potential to revolutionize therapeutic approaches.